“qwert” or “asdfgh”), all kinds of names (e.g. Problematic are trivial words like “ABC” or keyboard sequences (e.g.
A password should be at least 8 characters long and, if possible, always consist of a combination of upper and lower case letters, numbers and special characters. For this purpose, you must first enter your e-mail address, which you provided as part of the clinical trial, as your user name and select your password (“login data”). You can access the eCOA application via the login function. The legal basis for data processing in this case is Art. by sending an e-mail to you register for the newsletter, we also store your IP address and the time of registration in order to fulfill our legal documentation obligations. Alternatively, you can revoke your consent at any time, e.g. To exercise the revocation, you will find a corresponding link at the end of each e-mail newsletter. The revocation of consent does not affect the lawfulness of the processing carried out on the basis of the consent until the revocation. You can revoke your consent to receive newsletters at any time with effect for the future towards EvidentIQ. The processing of your personal data in connection with the newsletter is based on your consent pursuant to Art. If you do not confirm your registration within 7 days, your information will be blocked and automatically deleted after one month.
This means that after your registration we will send you an e-mail to the e-mail address you provided, in which we ask you to confirm that you wish to receive the newsletter. In connection with your registration to receive the newsletter, we use the so-called double-opt-in procedure. To receive our newsletter, only your e-mail address is required.
If you have expressly consented, you will receive a newsletter on EvidentIQ products and services via e-mail.